Vignola P A, Aonuma K, Swaye P S, Rozanski J J, Blankstein R L, Benson J, Gosselin A J, Lister J W
J Am Coll Cardiol. 1984 Oct;4(4):812-9. doi: 10.1016/s0735-1097(84)80411-8.
During a period of 18 months beginning in January 1982, a total of 65 patients were referred to the Miami Heart Institute for evaluation of either aborted out of hospital sudden death, ventricular tachycardia resistant to standard clinically directed antiarrhythmic medication programs or high grade ventricular arrhythmia (Lown class greater than or equal to IV B) with or without syncope. After complete evaluation including cardiac catheterization in all but 1 patient, 17 patients were identified in whom no obvious cardiac disease could be found. Twelve of the 17 underwent right ventricular endomyocardial biopsy. Six of the 12 biopsies demonstrated clinically unsuspected lymphocytic myocarditis (Group A). Findings in three of the remaining six biopsies were consistent with an early cardiomyopathy and in three were completely normal (Group B). Retrospective review of the clinical, laboratory, electrophysiologic, hemodynamic and angiographic data failed to identify a marker that reliably separated Group A from Group B patients. In addition to antiarrhythmic therapy guided by laboratory electrophysiologic study, all Group A patients were treated with prednisone and azathioprine. After 6 months of immunosuppression, all patients with myocarditis were reevaluated in the hospital without antiarrhythmic medication. Ventricular tachycardia/fibrillation could not be provoked in the laboratory during repeat electrophysiologic testing in five of the six patients. Repeat myocardial biopsy after all immunosuppressive therapy had been discontinued revealed absence of inflammation associated with varying degrees of residual interstitial fibrosis. There were no deaths. It was concluded that a patient with an otherwise clinically silent lymphocytic myocarditis can present with potentially life-threatening ventricular arrhythmias.(ABSTRACT TRUNCATED AT 250 WORDS)
从1982年1月开始的18个月期间,共有65例患者被转诊至迈阿密心脏研究所,以评估院外猝死未遂、对标准临床指导抗心律失常药物方案耐药的室性心动过速或伴有或不伴有晕厥的高级别室性心律失常(洛恩分级大于或等于IV B级)。在完成包括除1例患者外所有患者的心脏导管检查在内的全面评估后,确定了17例未发现明显心脏病的患者。这17例患者中有12例接受了右心室心内膜活检。12例活检中有6例显示出临床未怀疑的淋巴细胞性心肌炎(A组)。其余6例活检中有3例的结果与早期心肌病一致,3例完全正常(B组)。对临床、实验室、电生理、血流动力学和血管造影数据的回顾性分析未能找到可靠区分A组和B组患者的标志物。除了实验室电生理研究指导下的抗心律失常治疗外,所有A组患者均接受泼尼松和硫唑嘌呤治疗。免疫抑制6个月后,所有心肌炎患者在未使用抗心律失常药物的情况下在医院重新进行评估。6例患者中有5例在重复电生理测试期间在实验室中未能诱发室性心动过速/心室颤动。在停止所有免疫抑制治疗后进行的重复心肌活检显示无炎症,伴有不同程度的残余间质纤维化。无死亡病例。得出的结论是,患有临床无症状的淋巴细胞性心肌炎的患者可能会出现潜在危及生命的室性心律失常。(摘要截短为250字)